Skip to content

Effects of acupuncture on anxiety, depression and quality of life of patients with coronary artery disease after percutaneous coronary intervention: study protocol for a randomized, blinded, placebo-controlled trial

Effects of acupuncture on anxiety, depression and quality of life of patients with coronary artery disease after percutaneous coronary intervention: study protocol for a randomized, blinded, placebo-controlled trial

Status
Unknown
Phases
Phase 1
Study type
Interventional
Source
TCTR
Registry ID
TCTR20220629008
Enrollment
74
Registered
2022-06-29
Start date
2022-07-10
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety and depression are prominent in patients after percutaneous coronary interventions (PCI) for coronary artery disease (CAD), thus affecting patients&#039

Interventions

Active or placebo acupuncture interventions were standardized. Acupuncture therapists had at least 5 years of professional undergraduate education in acupuncture and at least 4 years of experience in
3 weeks in total). The acupuncturist assessed the accuracy of the intervention after the last treatment for each patient.
Experimental Other
acupuncture therapy

Sponsors

Xiaoxia Wang
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. CAD patients with anxiety and depression after PCI; Hamilton Anxiety Rating Scale (HAMA) score at least7 points, and Hamilton Depression Rating Scale (HAMD) score at least14 points; 2.Aged 18 to 85; 3.No anti-anxiety or depression medication within the last 2 weeks; 4.Voluntarily accepted the random grouping and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Patients with combined severe or unstable cardiac, cerebral, hepatic, renal, endocrine, hematological and other medical diseases; 2.Patients with progressive development or very poor prognosis, such as severe infections, severe water-electrolyte disorders, acid-base imbalance; 3. Patients with severe anxiety and depression, requiring oral anti-anxiety and depression drugs; 4. Patients with severe cognitive dysfunction who are unable to communicate; 5.Pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
Hamilton Anxiety Scale (HAMA) 6 days The scale consists of 14 items, and each entry is scored on a scale of 0 to 3. The cumulative entry scores are summed to a total HAMA score, with a total score range of 0 to 42.

Secondary

MeasureTime frame
Hamilton Depression Scale (HAMD) 6 days We used a 17-item version for evaluation, with evaluation items including despair, anxiety, sleep disorders, weight, cognitive impairment, day and night change, and retardation.

Countries

China

Contacts

Public ContactQingyuan Ma

The First People's Hospital of Lianyungang

maxiaobai2021@126.com18846278434

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026